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AbstrACt
Introduction Pre-eclampsia is a major complication 
of pregnancy, globally responsible for 60 000 maternal 
deaths per year, and far more fetal losses. There is no 
definitive treatment other than delivery. A therapeutic 
that could quench the disease process would be useful 
to treat preterm pre-eclampsia, as it could allow these 
pregnancies to safely continue to a gestation where fetal 
outcomes are significantly improved. We have published 
preclinical data to show that metformin, a drug known 
to be safe in pregnancy and commonly used to treat 
gestational diabetes, has potent biological effects making 
it another promising candidate to treat pre-eclampsia. 
Here, we describe a phase II clinical trial to examine 
whether administering extended-release metformin may 
be effective in treating women with preterm pre-eclampsia 
(PI2 Trial).
Methods The PI2 Trial is a phase II, double blind, 
randomised controlled trial that aims to recruit 150 women 
with preterm pre-eclampsia (gestational age 26+0 to 31+6 
weeks) who are being managed expectantly. Participants 
will be randomised to receive either 3 g of metformin 
or placebo daily. The primary outcome is time from 
randomisation until delivery. A delay in delivery of 5 days is 
assumed to be clinically relevant. The secondary outcomes 
will be a maternal composite and neonatal composite 
outcome. All other outcomes will be exploratory. We will 
record adverse events.
Ethics and dissemination This study has ethical 
approval (Protocol number M16/09/037 Federal Wide 
Assurance Number 00001372, Institutional Review Board 
Number IRB0005239), is registered with the Pan African 
Clinical Trial Registry (PACTR201608001752102) and 
the South African Medicine Control Council (20170322). 
Data will be presented at international conferences and 
published in peer-reviewed journals.
trial registration number PACTR201608001752102; 
Pre-results.
IntroduCtIon  
Pre-eclampsia is one of the most serious 
complications of pregnancy affecting 5% of 
pregnancies worldwide.1 It is a multisystem 
disorder involving maternal vessels (causing 
hypertension and endothelial dysfunction), 
the kidneys, the liver, the lungs, the haema-
tological system, the cardiovascular system 
and the fetoplacental unit.2 In its most severe 
form, it affects the brain, causing seizures 
(eclampsia), cerebrovascular events and even 
death.
It is a leading cause of maternal and 
fetal/neonatal morbidity.3 Globally, pre-ec-
lampsia is responsible for >60 000 maternal 
deaths annually4 and it is estimated that 
for every pre-eclampsia related death there 
are 50 to 100 other women who experi-
ence significant morbidity associated with 
pre-eclampsia.5
At present, the only treatment available 
for pre-eclampsia is termination/delivery 
of the pregnancy. This poses a difficult 
clinical dilemma in the setting of preterm 
pre-eclampsia. Clinicians are often forced to 
deliver early to prevent disease progression 
and major maternal morbidity (ie, severe 
maternal organ injury), but in doing so, inflict 
severe prematurity on the fetus. In particular, 
fetuses delivered at less than 33 weeks’ gesta-
tion are at significant risk of severe disability 
strengths and limitation of this study
 ► This is a protocol for a randomised, double blind, 
placebo-controlled clinical trial.
 ► This is the first trial to assess whether metformin is 
a treatment option for pre-eclampsia.
 ► We plan to recruit 150 participants which provides 
sufficient power for our primary outcome (time from 
randomisation to delivery).
 ► Our trial may be underpowered to show improve-
ments in maternal and perinatal outcomes.
 ► If the trial yields a positive result, larger multicentre 
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including cerebral palsy, stroke (intracerebral bleeding), 
retinopathy of prematurity, chronic lung disease and 
death.6
We have recently completed a phase II, double blind, 
randomised controlled trial, the Pre-eclampsia Interven-
tion with Esomeprazole (PIE) trial, to evaluate whether 
40 mg of esomeprazole was a possible treatment for early 
onset pre-eclampsia. This trial showed no between-group 
differences in median time from randomisation to delivery 
(11·4 days in the esomeprazole group and 8·3 days in the 
placebo group [95% CI −2·9 to 8·8, p=0·31]).7 8 Here, we 
propose metformin as the next therapeutic candidate to 
test in a clinical trial for preterm pre-eclampsia.
Metformin is a promising therapeutic candidate as 
it has been shown to reduce soluble fms-like tyrosine 
kinase 1 (sFlt-1) and soluble endoglin (sEng) secre-
tion from endothelial cells and primary trophoblasts.9 
These key anti-angiogenic molecules released from the 
placenta are responsible for the widespread endothelial 
dysfunction and impaired vascular relaxation observed 
in pre-eclampsia. Reduced angiogenesis is also thought 
to contribute to placental hypoxia and to the develop-
ment of pre-eclampsia. Metformin has also been shown 
to improve endothelial dysfunction, improve blood 
vessel relaxation and promote angiogenesis.9 Given these 
multiple potential effects, metformin is a particularly 
promising therapeutic candidate.
objECtIvEs
The primary objective is to examine whether 3 g of 
metformin XR can safely prolong gestation among 
women with preterm pre-eclampsia who are being 
managed expectantly, compared with expectant manage-
ment alone. A prolongation of 5 or more days will be 
considered clinically significant.
The secondary objectives are to examine whether 
metformin can improve maternal and neonatal composite 
outcomes.
MEthods
The full protocol is included as supplementary informa-
tion (online supplementary file 1).
study design
Phase II hospital based, double blind, randomised, place-
bo-controlled trial.
study population
Pregnant women diagnosed with pre-eclampsia at a gesta-
tional age between 26+0 weeks to 31+6 weeks at Tyger-
berg Hospital (Western Cape Province of South Africa) 
will be invited to participate. To be eligible for this study 
the treating clinicians need to have made an initial 
assessment and deemed that the patient is suitable for 
expectant management and delivery is not immediately 
required or anticipated in the next 48 hours.
Inclusion criteria
We will recruit women with a singleton pregnancy diag-
nosed with pre-eclampsia and chronic hypertension with 
superimposed pre-eclampsia defined according to the 
criteria published by The International Society for the 
Study of Hypertension In Pregnancy,10 and require the 
presence of significant proteinuria (more than 300 mg in 
a 24 hours urine collection). Some women only present 
for antenatal care after 20 weeks gestation. We will 
include these women and classify these women as unclas-
sified proteinuric hypertension during the pregnancy 
according to the classification of Davey and MacGilli-
vray.11 Postpartum, these women will be reclassified as 
having had pre-eclampsia or chronic hypertension based 
on their blood pressure and need for medication more 
than 6 weeks after the due date.
Gestational age will be determined by either period 
dates (if the woman is certain of her last menstrual 
period) or by an early or mid trimester pregnancy ultra-
sound. If the gestational age is uncertain, we will recruit 
participants with an estimated fetal weight between 500 
and 1800 g, determined by ultrasound performed at 
presentation. A full list of inclusion criteria is provided 
in box 1.
Exclusion criteria
Exclusion criteria include women with established 
maternal or fetal compromise that necessitates delivery 
within 48 hours, the current use of metformin, contrain-
dications to the use of metformin or the use of medica-
tions that interact with metformin. A full list of exclusion 
criteria is provided in box 2.
Participant enrolment
Participants will be identified after they have been 
admitted to the tertiary referral centre with a diagnosis 
of preterm pre-eclampsia for expectant management. An 
box 1 Inclusion criteria
A diagnosis of one of the following
 ► Pre-eclampsia
 ► Gestational hypertension with evidence of pre-eclampsia
 ► Preexisting hypertension with evidence of pre-eclampsia
 ► Unclassified proteinuric hypertension
And all of the following is present
 ► Gestational age between 26+0 weeks and 31+6 weeks
 ► Estimated fetal weight by ultrasound between 500 g and 1800 g (if 
gestation is not certain)
 ► Singleton pregnancy
 ► The managing clinicians have made the assessment to proceed 
with expectant management and that delivery is not expected with-
in 48 hours
 ► The managing clinician and neonatologist believe that the fetus 
could potentially be delivered in a viable condition
 ► No suspicions of a major fetal anomaly or malformation.
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information leaflet will be given to all potential partici-
pants and written informed consent will be obtained 
(online supplementary file 2 and 3).
randomisation and allocation concealment
After informed consent, participants will be randomised to 
metformin or placebo in a 1:1 ratio. An online, web-based 
sequence generator system linked with codes for placebo 
and treatment tablets will be used. Both researchers and 
participants will be blinded.
The gestational age at diagnosis is likely to affect allow-
able length of pregnancy prolongation. To ensure treat-
ment group allocation is balanced for this potentially 
confounding variable, we will stratify by gestational age. 
Strata 1 includes women with pregnancies of gestational 
age of 26+0 up to and including 28+6 weeks (500 to 1200 g 
if gestation is unknown). Strata 2 includes women with 
pregnancies of gestational age 29+0 up to and including 
31+6 weeks (1200 to 1800 g if gestation is unknown). 
Thus, randomisation will include blocking within each 
gestational age stratum. We will use blocks of four to 
six with the size and order randomly assigned.
Once the participants have been randomised, the treat-
ment pack with the same code will be allocated to the 
participant. All treatment packs will be identical and will 
contain either active tablets or placebo. The researchers 
will have no access to the randomisation list. This 
process will ensure that there is allocation concealment 
throughout the conduct of the trial.
Each participant will be given an individual treatment 
pack containing either 500 mg of metformin XR or 
identical placebo tablets which have been produced by 
Merck (http://www. merck. com/ index. html). Labelling, 
storage and preparation will be done according to the 
requirements of the Medicines for Human Use (Clin-
ical Trials) regulations. Participants will be started on six 
tablets daily in divided doses. If side effects develop the 
dose will be decreased until the side effects improve and 
then increased again if tolerated.
Co-interventions
Participants will remain under the care of the hospital 
treating team and the study will not alter or interfere with 
the routine care provided for women with preterm pre-ec-
lampsia, including the decision for delivery. Management 
for preterm pre-eclampsia involves admission to hospital 
with close maternal and fetal surveillance. Maternal 
surveillance includes four times an hour blood pressure 
measurement, two times per day clinical assessment, daily 
urinalysis and two times per week assessments with blood 
tests (full blood count, renal function tests and hepato-
cellular enzymes if haemolysis, elevated liver enzymes 
and low platelets syndrome is suspected) and 24 hours 
urinary protein measurement on admission. Fetal surveil-
lance includes six times an hour cardiotocography and 
ultrasound assessments every 2 weeks (or more frequently 
if clinically indicated) for Doppler velocimetry of the 
umbilical artery, middle cerebral artery, ductus venosus, 
amniotic fluid volume assessment and fetal growth.
All participants will receive two doses of betamethasone 
24 hours apart to reduce the risks of neonatal respiratory 
distress syndrome, intracranial haemorrhage and necro-
tising enterocolitis for the neonate. A single repeat dose 
will be given 1 week later as per hospital protocol.12 Most 
participants will be on antihypertensive treatment, and the 
dose and number of antihypertensives will be recorded. 
All women should already be receiving calcium, iron and 
folic acid supplementation.
Clinical care will be left up to the discretion of the clin-
ical team. The indication for delivery will be a clinical 
decision. Indications for delivery may include inability 
to achieve blood pressure control, the development of 
major maternal or fetal complications or intrauterine 
fetal death. Expectant management will usually end at a 
gestation of 34 weeks.
sample collection
Blood samples will be routinely collected two times a 
week. The routine blood samples include measurements 
of the haemoglobin, the platelet count and the urea and 
creatinine levels. These will be used by the managing 
clinicians to determine disease severity and may trigger 
delivery.
outcomes
The primary outcome is to examine whether up to 3 g of 
metformin daily can safely prolong gestation in women 
with preterm pre-eclampsia diagnosed between 26+0 to 
31+6 weeks gestation, compared with standard of care, 
box 2 Exclusion criteria
Any of the following at the initial assessment
 ► The patient is unable or unwilling to give consent
 ► Established fetal compromise that necessitates delivery
 ► The presence of: eclampsia
a. Severe hypertension, defined as a systolic blood pressure great-
er than or equal to 160 mm Hg or diastolic blood pressure great-
er than or equal to 110 mm Hg that cannot be controlled with 
antihypertensive medication within 48 hours of admission
b. Cerebrovascular event
c. Posterior reversible encephalopathy syndrome
d. Severe renal impairment, defined as a creatinine level  ≥125 
μmol/l or a need for dialysis
e. Pulmonary oedema
f. Left-sided heart failure
g. Disseminated intravascular coagulation
h. Platelet count <50×109
i. Haemolysis, elevated liver enzymes and low platelets syndrome
j. Liver transaminases >500 IU/L
k. Liver haematoma or rupture
l. Severe ascites
 ► Diabetes
 ► Current use of metformin
 ► Contraindications or a hypersensitivity reaction to the use of 
metformin
 ► Current use of a drug that may be affected by metformin P
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expectant management alone. This is set in a superiority 
framework with two-sided hypothesis regions for all statis-
tical testing. A prolongation of 5 days or longer will be 
considered clinically significant.
The secondary outcome is to determine whether 
metformin improves maternal composite and neonatal 
composite outcomes. The composite maternal outcome 
includes maternal death, eclampsia, pulmonary oedema, 
severe renal impairment or the need for dialysis, a cere-
bral vascular event, the development of a liver haema-
toma or rupture and placental abruption. The composite 
neonatal outcome will include neonatal death within 6 
weeks after the due date, grade III or IV intraventricular 
haemorrhage defined enlarged ventricles associated 
with haemorrhage or haemorrhage extending into the 
cerebral tissue around the ventricles on imaging, necro-
tising enterocolitis defined on radiographic studies or 
bronchopulmonary dysplasia defined as needing oxygen 
at day 28 of life, either on a ventilator, by continuous 
positive airway pressure or via a nasal catheter. See box 3 
.
All other outcomes, including outcomes nested within 
the composite secondary outcomes will be classified as 
exploratory outcomes. These are listed in box 4.
Withdrawal from the study
All participants will be informed that they are free to 
withdraw from the study at any time, and that this will 
not affect their clinical care. In the event of withdrawal, 
we will seek the patient’s permission to use their clinical 
information and laboratory samples collected thus far in 
subsequent analyses.
duration of the trial
It is anticipated that the study will be completed in 
approximately 3 years (2018 to 2020). In our previous PIE 
study, we included 120 women in 15 months.8
Confidentiality
Patient confidentiality will be protected according to the 
regulations set forth by Stellenbosch University’s Human 
Research Ethics Committee or Institutional Review Board.
data management and statistical analysis
Data will be collected prospectively using a REDCap data-
base.13 Data entry and checking will be continuous, and 
queries will be addressed contemporaneously to ensure 
clarification without delay. All data will be double checked 
for accuracy.
box 3 secondary outcomes
secondary outcomes
Composite maternal outcome:
 ► Maternal death 
 ► Eclampsia
 ► Pulmonary oedema
 ► Severe renal impairment or dialysis
 ► Cerebral vascular event
 ► Liver haematoma or rupture
 ► Placental abruption
Composite neonatal outcome:
 ► Neonatal death within 6 weeks after the due date
 ► Grade III or IV intraventricular haemorrhage
 ► Necrotising enterocolitis (diagnosed on radiological studies)
 ► Bronchopulmonary dysplasia (defined as needing oxygen at day 28 
of life, either on a ventilator, by continuous positive airway pres-
sure or via a nasal catheter)
box 4 Exploratory outcomes
Exploratory outcomes
Maternal exploratory outcomes:
 ► Maternal death
 ► Eclampsia
 ► Pulmonary oedema
 ► Severe renal impairment or dialysis
 ► Cerebral vascular event
 ► Liver haematoma or rupture
 ► Abruptio placentae
 ► Admission to a high care or intensive care unit
 ► Posterior reversible encephalopathy syndrome
 ► Left ventricular failure
 ► Serum creatinine >125 μmol/l
 ► Proteinuria >3 g/24 hours
 ► Severe hypertension
 ► Disseminated intravascular coagulation
 ► Platelet count less than 50×109
 ► Haemolysis, elevated liver enzymes and low platelets syndrome
 ► Liver transaminases >500 IU/L
 ► Placental abruption
 ► Mode of delivery
 ► Use of antihypertensive agents
 ► Major postpartum haemorrhage
 ► Thromboembolic disease
 ► Moderate or severe ascites
Fetal exploratory outcomes:
 ► Reversed a-wave in the ductus venosus on fetal ultrasound
 ► Significant changes in fetal heart rate patterns on the non-stress 
test that necessitate delivery
 ► Intrauterine fetal demise
 ► Fetal growth restriction at birth
 ► Persistent reversed flow in the umbilical artery
 ► Redistribution in the middle cerebral artery
neonatal exploratory outcomes:
 ► Neonatal death within 6 weeks after the due date
 ► Grade III or IV intraventricular haemorrhage
 ► Necrotising enterocolitis
 ► Bronchopulmonary dysplasia
 ► APGAR score <7 at 5 min
 ► Umbilical artery PH <7.05
 ► Umbilical artery lactate
 ► Surfactant use
 ► Neonatal intensive care or special care unit admission
 ► Intubation and mechanical ventilation
 ► Continuous positive airway pressure support
 ► Grade III/IV hyaline membrane disease hospital stay
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The patient characteristics, by treatment group at 
randomisation, will be presented as mean (SD), median 
(25th to 75th percentile), minimum, maximum and 
count (%) depending on type and distribution.
The primary outcome will be measured from the time 
of randomisation to delivery. Secondary maternal and 
neonatal outcomes will be measured from the time of 
recruitment until 6 weeks after the due date. The signifi-
cance level for the primary outcome is set at 0.05 and all 
hypothesis testing will be two-sided. If, and only if, there 
is a significant difference for the primary outcome, the 
two secondary outcomes will be tested at a significance 
level of 0.025. Standard 95% CI will be used to present 
the analysis of the primary outcome. The width of the 
CI used will be adjusted for the secondary outcomes if 
tested. For raw results data, the primary outcome will 
be summarised using median (25th to 75th percentile) 
along with minimum and maximum values.
All secondary outcomes and exploratory outcomes of 
inter-test will be presented by number (%) by treatment 
arm. Primary outcome effect size will be presented as 
difference in medians and 95% CI, adjusted for gesta-
tional age strata based on the quantile regression model. 
P values will be reported associated with 95% CI for the 
secondary outcomes if tested. Exploratory outcomes will 
be presented with 95% CI.
Modelling will use quantile regression to assess differ-
ence in median prolongation between groups. This will be 
supplemented by survival analysis (ie, time until delivery), 
using Cox proportional hazards regression (CPH) and 
Kaplan-Meier survivorship curves. Survival outcomes will 
not be subject to hypothesis testing. For both quantile 
regression and survival analysis effect estimates will be 
presented as group difference with 95% CI.
The number of events for each of the composite binary 
outcomes is likely to be small. An exact logistic regression 
model containing treatment group and gestational age 
strata will be used. In the event that it is not possible to 
obtain estimates, due to small counts each hypothesis will 
be tested, unadjusted for gestational strata, using Fish-
er’s exact test. Point estimates of percentage and exact 
95% CI will also be provided.
For the primary outcome a covariate adjusted analysis 
with both treatment group and gestational age design-
based strata modelled as fixed will constitute the primary 
analysis outcome. Unadjusted and adjusted CPH analysis 
are only supplemental to this primary analysis. For the 
secondary outcomes composite binary outcomes will be 
modelled using a logistic regression model containing 
both treatment group and gestation aged based strata.
The sensitivity analyses that will be conducted on 
the primary outcome are; first, the treatment received; 
second, gestational age as an effect modifier; third, 
covariate adjusted for an estimated fetal weight less than 
the 10th and 3rd centile on ultrasound at the time of rando-
misation and absent umbilical artery end diastolic flow as 
these are more likely to be associated with shorter rando-
misation to delivery times and lastly, a survival analysis 
will be performed using CPH adjusted for gestational age 
strata and Kaplan-Meier survivorship curves.
No sensitivity analysis for primary outcome outcomes 
is planned for missing data as we expect these mothers 
not to have missing outcome data or baseline measured 
pre-treatment covariates. If the neonate is lost to follow-up 
the outcome will be set to missing, a sensitivity analysis 
will be performed to assess strength of inference given 
pattern of missingness by setting missing values to no 
event, mean event rate or event to assess dependence on 
inference on the unknown outcomes.
Statistical software used is Stata V.15 (StataCorp. 2017. 
Stata Statistical Software: Release 15). The trial presen-
tation will meet the CONSORT statement requirements 
(http://www. consort- statement. org/).
sample size and stratification according to gestation at 
recruitment
The primary research question is whether metformin 
will result in a gain in the median length of gestation 
compared with placebo therapy. A prolongation of more 
than 5 days will be considered clinically significant. Given 
the focus on median prolongation and the skewed nature 
of the gestation prolongation (seen in the two trials listed 
below) we based sample size calculations on the geometric 
mean ratio . Analysis was performed both using PASS 
13 (Power Analysis and Sample Size Software [2014]. 
NCSS, LLC.) and the Powercal programme running in 
Stata V.15.14
We have two sources for data on the prolongation of 
gestation in pre-eclamptic mothers receiving expectant 
management which were both performed at the same 
hospital where we plan to run this trial (Tygerberg 
Hospital). Hall et al, in the largest descriptive study 
on expectant management of preterm pre-eclampsia, 
reported a mean gestation prolongation of 11 (SD 7) days 
equivalent to a coefficient of variation (CV) = 0.64,15 and 
the PIE trial,8 where patients randomised to the placebo 
arm had an overall mean prolongation of 13.1 (SD 12.2) 
days, a CV = 0.93.8 In this study for mothers entering at 
gestations greater than 29 weeks, the CV = 0.8. We have 
therefore chosen to use a CV = 1.0, slightly larger than 
the 0.93 found in our PIE study, to allow for adequate 
power if greater variability in prolongation times occurs 
in PI2 Trial.
For 90% power, with a two-sided alpha set at 0.05, 
control median prolongation of 8.3 days and prolonga-
tion of gestation of 5 days with the measure of variability 
used in this analysis being the CV = (data SD)/data mean), 
we require 65 participants per group. Allowing for 10 
dropouts per group we require 75 participants per arm 
and therefore a total of 150 participants.
The gestational age at diagnosis is likely to affect allow-
able length of pregnancy prolongation. For instance, those 
diagnosed at 31+6 will be delivered at 34 weeks. Thus, 
such patients will have a maximum length of pregnancy 
prolongation of 15 days. In contrast, those diagnosed at 
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prolongation. Further it is possible that metformin effi-
cacy may vary with gestational age at diagnosis. To ensure 
treatment group allocation is balanced for this potential 
variable, we will stratify randomisation into strata based 
on gestational age. Stratum 1 will include pregnancies of 
a gestational age of 26 weeks 0 days up to and including 
28 weeks and 6 days. Stratum 2 will include pregnancies 
from 29 weeks and 0 days up to and including 31 weeks 
and 6 days.
More detail is available in the trial statistical analysis 
plan (online supplementary file 4).
Adverse events
Reporting and handling of adverse events and serious 
adverse will be in accordance with the good clinical 
practice guidelines.
unblinding
Given that the safety profile of metformin in pregnancy 
is well established, we anticipate the need for unblinding 
to be unlikely. However, we will have the following proce-
dures in place should unblinding be required. Sheets 
with lists of 25 randomisation codes each will be sealed 
in individual, signed, numbered envelopes. If unblinding 
is requested, the relevant envelope will be opened by a 
person not involved in the trial in the presence of two 
witnesses, the group allocation read and the list re-sealed 
in an envelope and signed. The randomisation envelopes 
will be accessible at all times to the principal investigator 
who will be contactable by mobile telephone. The prin-
cipal investigator will co-ordinate this process.
Early termination of the trial
If for any reason, there is a need to stop the trial prema-
turely this decision will be taken by the data and safety 
monitoring committee.
Patient and public involvement
Patients and the public were not involved in the develop-
ment of the research question, the design of the study, 
the conduct or recruitment and the burden of the inter-
vention was not assessed by the patients or the public. The 
results of the study will be emailed to the participants.
dIsCussIon
Pre-eclampsia is a serious life-threatening condition for 
both the mother and fetus and is associated with severe 
maternal and perinatal morbidity. If a treatment were 
to be discovered, it would have a major impact on both 
maternal and perinatal health. An ideal drug would 
ameliorate the biological disease process of pre-eclampsia 
in the mother and placenta, reduce the risk of serious 
complications from developing and allow pregnancies 
that were complicated by the disease at an early gestation 
to gain gestation without putting the mother and fetus at 
significantly increased risk.
Recently a number of clinical trials have been proposed 
for assessing novel treatments for pre-eclampsia, but 
only a few have been completed. Our group has recently 
completed the PIE trial assessing esomeprazole to treat 
preterm pre-eclampsia.8 In this trial a daily dose of 
40 mg esomeprazole did not prolong gestation or have 
any effect on biomarkers associated with pre-eclampsia. 
Sildenafil was assessed in a single site, double blind, 
randomised controlled trial in Brazil.16 Over a 28 month 
period, 100 women were recruited and results were avail-
able for 93 women. There was a significant prolonga-
tion of gestation in the sildenafil group of 4 days, but 
given that sildenafil is a vasodilator it is possible that this 
prolongation in gestation may have occurred because 
the drug decreased blood pressure and mitigated a 
clinical reason to deliver, rather than temporising 
disease progression. Antithrombin was assessed to treat 
preterm pre-eclampsia in the PRESERVE-1 trial which 
enrolled 120 women from 23 tertiary hospitals over 28 
months (ISRCTN23410175).17 There was no difference 
in prolongation of pregnancy or composite neonatal 
outcomes.18 Trials assessing serelaxin (NCT01566630), 
pravastatin, high doses of antithrombin19 and celecoxib 
(NCT00442676) have been attempted, but all were 
terminated due to poor recruitment.
It is known that the pre-eclamptic placenta releases 
anti-angiogenic sFlt-1 and sEng into the maternal circu-
lation, causing widespread maternal endothelial dysfunc-
tion and organ injury.20 A drug that can decrease sFlt-1 
and sEng production and decrease endothelial dysfunc-
tion may be a potential treatment for pre-eclampsia. We 
have generated preclinical data suggesting metformin 
may have such actions.9 Based on this preclinical data, we 
are now proposing to undertake this phase II randomised 
clinical trial.
We propose recruiting 150 women at Tygerberg Hospital 
in the Western Cape Province of South Africa. There are 
advantages to running the trial at this site. South Africa 
has a very high incidence of pre-eclampsia. Tygerberg 
Hospital is a tertiary referral centre with a neonatal inten-
sive care unit, a maternal critical care unit and an adult 
intensive care unit. It is an academic centre that actively 
contributes to the global scientific literature and our 
team has recently completed the PIE trial at this research 
unit. We will make use of the systems set up by this trial. 
Thus, we believe running this trial at Tygerberg Hospital 
represents a balance between obtaining sufficient number 
of cases of preterm pre-eclampsia, performing the trial 
in a cost-effective manner and offering modern obstetric 
and perinatal care, making the results potentially general-
isable to both developed and developing countries.
Metformin is known to be safe in pregnancy and is 
considered a category B drug in pregnancy (by the Food 
and Drug Administration).21 There are numerous studies 
of metformin for the treatment of diabetes and polycystic 
ovarian syndrome in pregnancy which have shown no 
adverse fetal effects when used in the first, second and 
third trimesters.22–27 Metformin does cross the placental 
barrier and it’s long-term effect on fetal development is 
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and Gynaecologists (ACOG) practice bulletin has 
concluded that it can reasonably be used in pregnancy.28
In strong support of our preclinical data are meta-anal-
yses of clinical trial data that have shown a decrease in the 
incidence of hypertensive disorders when metformin has 
been used for other indications.29 Excitingly, a randomised 
trial by the Fetal Medicine Foundation (for obese women 
without diabetes) reported that metformin significantly 
reduced the incidence of pre-eclampsia by as much as 
76%.30 The EMPOWaR trial also evaluated maternal 
and fetal effects of metformin in obese women.31 While 
reporting no decrease in the incidence of hypertensive 
disorders of pregnancy with metformin, the most likely 
reason for this difference was poor compliance.32
We have powered our study for the primary outcome, 
which is to show whether metformin can safely prolong 
gestation for a further 5 days in mothers being expec-
tantly managed for preterm pre-eclampsia. This surrogate 
primary outcome marker has been chosen as it provides 
a sample size that is feasible and attainable for a phase 
II study to assess efficacy. A limitation in this trial is that 
we have not specifically powered to detect improvements 
in maternal or neonatal outcomes (although these are 
planned secondary outcomes). If this trial yields a positive 
result, a further phase III multicentre randomised trial 
that is sufficiently powered, may be required to be suffi-
ciently powered to demonstrate improvements in clinical 
outcomes.
As we did for the PIE trial, we will measure biomarkers 
that reflect disease severity. We will measure circulating 
levels of sFlt-1 and sEng, among others, in serial samples 
obtained from the mother. These anti-angiogenic factors 
are considered to play an important role in inciting 
maternal endothelial dysfunction and end-organ injury 
seen in pre-eclampsia. Furthermore, we will measure 
expression of key molecules in the placental samples 
obtained at delivery.
Pre-eclampsia kills mothers, fetuses and neonates and is 
responsible for severe maternal and neonatal morbidity. 
This is especially the case in the developing world where 
there is a lack of resources, including staff, equipment 
and finances. If a treatment were to be discovered, it 
would have dramatic effects on maternal and neonatal 
outcomes. Metformin has shown potential as a thera-
peutic agent in preclinical work on pre-eclampsia. Further 
advantages of metformin XR are that it is available in a 
long acting formulation, it is safe during pregnancy and 
it is not expensive. This makes it an ideal candidate as 
a global therapeutic for pre-eclampsia. It is therefore 
imperative for this trial to be performed. If metformin 
were proven to be effective at prolonging gestation in 
early onset pre-eclampsia it could play an important 
role in decreasing the clinical burden of this dangerous 
condition.
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